Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | GELATO: carboplatin and atezolizumab in advanced lobular BC

Leonie Voorwerk • 14 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Atezolizumab Carboplatin Checkpoint Inhibitors
GELATO

Leonie Voorwerk, MD, The Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the GELATO trial (NCT03147040), a single-arm, multicenter, non-randomized Phase II trial testing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Leonie Voorwerk

3:22
Critical role of eosinophils during response to ICI blockade
Leonie Voorwerk • 18 Sep 2020

Related Videos

1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
1:17
Avoiding unnecessary mastectomies in breast cancer
Federica Martorana • 25 Mar 2024
The content of VJOncology is intended for healthcare professionals